News
Artelo Biosciences announces positive Phase 1 results for ART26.12, a novel FABP5 inhibitor for pain management.
In these OA studies with ART26.12, the FABP5 inhibitor demonstrated efficacy comparable to naproxen, a commonly prescribed nonsteroidal anti-inflammatory drug (NSAID), with ART26.12 maintaining ...
Investing.com -- Artelo Biosciences Inc (NASDAQ: ARTL) stock surged 10% following the presentation of positive preclinical data for its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, ...
A new study has found that linoleic acid, a common fat found in seed oils like soybean and safflower oil, can increase the ...
14d
InvestorsHub on MSNArtelo Biosciences Shares Climb on Promising Preclinical Osteoarthritis Pain DataArtelo Biosciences Inc (NASDAQ:ARTL) saw its stock jump 10% after unveiling encouraging preclinical results for its lead drug ...
A new preclinical study from Weill Cornell Medicine reveals that linoleic acid, a type of omega-6 fatty acid commonly found ...
Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was ...
The dietary intake of LCFAs may also influence the progression of allergic diseases. Research indicates that in the pathogenesis of allergic asthma, fatty acid binding protein 5 (FABP5) is regulated ...
Importantly, FABPs, especially those that are expressed by adipocytes and macrophages (FABP4 and FABP5, respectively) have key roles in regulating systemic metabolism and are important mediators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results